Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 1 Rectal Neoplasms 1 Plasmacytoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Margins of Excision 1 Homologous Recombination Deficient Solid Tumors 1 Drug-Related Side Effects and Adverse Reactions 1 Colorectal Neoplasms 1 Colonic Neoplasms 1

Interventions

Oxaliplatin 180 Capecitabine 174 Fluorouracil 154 Radiotherapy 107 Leucovorin 107 Irinotecan 93 Bevacizumab 69 Surgical Procedures, Operative 49 Cetuximab 39 Drug Therapy 38 Radiation 35 Neoadjuvant Therapy 33 Folfox protocol 29 Chemoradiotherapy 29 XELOX 22 Magnetic Resonance Spectroscopy 21 Chemotherapy, Adjuvant 21 Radiotherapy, Intensity-Modulated 19 Surveys and Questionnaires 17 Proctectomy 16 Biopsy 16 Early Intervention, Educational 14 trifluridine tipiracil drug combination 12 Panitumumab 12 Floxuridine 12 tislelizumab 11 regorafenib 11 Nivolumab 11 Laparoscopy 11 Celecoxib 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rectal Neoplasms × Drug Combinations × Clear all

NCT04389086 2022-09-06

PelvEx II

Catharina Ziekenhuis Eindhoven

Phase 3 Recruiting

Gastrointestinal

Margins of Excision, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡